HK1057170A1 - Quetiapine for treating of dyskinesia in non-psychotic patients - Google Patents

Quetiapine for treating of dyskinesia in non-psychotic patients

Info

Publication number
HK1057170A1
HK1057170A1 HK04100061A HK04100061A HK1057170A1 HK 1057170 A1 HK1057170 A1 HK 1057170A1 HK 04100061 A HK04100061 A HK 04100061A HK 04100061 A HK04100061 A HK 04100061A HK 1057170 A1 HK1057170 A1 HK 1057170A1
Authority
HK
Hong Kong
Prior art keywords
quetiapine
treating
dopaminergic
dyskinesia
disease
Prior art date
Application number
HK04100061A
Other languages
English (en)
Inventor
Jeffrey Goldstein
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1057170A1 publication Critical patent/HK1057170A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
HK04100061A 2000-12-20 2004-01-05 Quetiapine for treating of dyskinesia in non-psychotic patients HK1057170A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28758200P 2000-12-20 2000-12-20
PCT/SE2001/002820 WO2002049652A1 (en) 2000-12-20 2001-12-18 Method of treatment

Publications (1)

Publication Number Publication Date
HK1057170A1 true HK1057170A1 (en) 2004-03-19

Family

ID=23103533

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100061A HK1057170A1 (en) 2000-12-20 2004-01-05 Quetiapine for treating of dyskinesia in non-psychotic patients

Country Status (9)

Country Link
US (1) US20040058909A1 (de)
EP (1) EP1345610B1 (de)
JP (1) JP2004516271A (de)
AT (1) ATE347364T1 (de)
AU (1) AU2002216557A1 (de)
DE (1) DE60125062T2 (de)
ES (1) ES2275619T3 (de)
HK (1) HK1057170A1 (de)
WO (1) WO2002049652A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
FR2888116A1 (fr) 2005-07-08 2007-01-12 Sod Conseils Rech Applic Derives de thiazoles pour traiter les dyskinesies
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
ITMI20100260A1 (it) * 2010-02-19 2011-08-20 Giulio Scigliano Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
WO2018191450A2 (en) * 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds

Also Published As

Publication number Publication date
WO2002049652A1 (en) 2002-06-27
DE60125062D1 (de) 2007-01-18
DE60125062T2 (de) 2007-05-31
JP2004516271A (ja) 2004-06-03
ES2275619T3 (es) 2007-06-16
AU2002216557A1 (en) 2002-07-01
EP1345610B1 (de) 2006-12-06
US20040058909A1 (en) 2004-03-25
EP1345610A1 (de) 2003-09-24
ATE347364T1 (de) 2006-12-15

Similar Documents

Publication Publication Date Title
CO5601022A2 (es) Metodos para tratar pacientes que padecen transtornos de movimiento
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
IL156122A0 (en) Geldanamycin derivative and method of treating cancer using same
NO20014842L (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
EA200101089A1 (ru) Новый способ лечения
HUP0101645A2 (hu) Riluzol és L-DOPA kombinációi a Parkinson kór kezelésére
MY164077A (en) Compositions and uses of et743 for treating cancer
HK1057170A1 (en) Quetiapine for treating of dyskinesia in non-psychotic patients
WO2002056745A3 (en) Method of treating parkinson's disease
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
WO2000057867A3 (en) Improved cancer treatment with temozolomide
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
TR200302008T4 (tr) Dış retina bozukluklarının tedavisine yönelik bir ilaç üretiminde beta-adrenoseptör antagonistlerin kullanımı.
IL159770A0 (en) Calcium salts with cytotoxic activity
WO2001042205A3 (en) Treatment of inflammatory bowel disease with vitamin d compounds
EP1161254A4 (de) Behandlung autoimmuner krankheiten mit amerikanischem ginseng extrakt
RU2002105074A (ru) Способ лечения и профилактики развития гипертрофических и келоидных рубцов
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
IL164092A0 (en) The use of devazepide as analgesic agent
IL157408A (en) Use of elemental calcium in the manufacture of a medicament to reduce prostate cancer risk
UA36361A (uk) Спосіб лікування захворювань щитовидної залози
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101218